{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:29:36Z","timestamp":1782840576840,"version":"3.54.5"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>T-cell redirecting therapies, including T-cell engagers (TCEs) and Chimeric Antigen Receptor T-cell (CAR-T), are under investigation in metastatic castration-resistant prostate cancer (mCRPC). Despite their promising therapeutic potential, these therapies remain in early stages of development due to treatment-related adverse events (TRAEs). This study aims to quantify the frequency and severity of adverse events in clinical trials with a pooled analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, CINHAL, Scopus, and Ovid was conducted to identify clinical trials evaluating TCEs or CAR-T in patients with mCRPC. Types and frequencies of TRAEs were collected and analyzed using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen TCEs trials involving 861 patients and 5 CAR-T trials involving 55 patients were identified. Cytokine release syndrome occurred in 59% (95% confidence interval: 25, 86) and 43% (28, 59) with TCEs and CAR-T, respectively. Neurologic TRAEs occurred in 39% (22, 60) with CAR-T compared to 9% (4, 17) with TCEs (P\u2009&amp;lt;\u20090.0001). Hematologic and hepatic TRAEs occurred in 34% (8, 75) and 25% (12, 44) with CAR-T, compared to 23% (7, 56) and 33% (12, 64) with TCEs, respectively. Musculoskeletal\/dermatologic TRAEs occurred in 33% (24, 42) and 29% (8, 58) with TCEs and CAR-T, respectively. Renal and gastrointestinal TRAEs occurred in 21% (5, 51) and 14% (2, 43) with CAR-T, compared to 15% (8, 25) and 21% (12, 36) with TCEs, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data underscore the TRAE profiles associated with these therapies and emphasize the importance of differentiating off-target toxicities from immune effector cell\u2014toxicities to inform the development of effective TRAE mitigation strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag172","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:46:18Z","timestamp":1777376778000},"source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis"],"prefix":"10.1093","volume":"31","author":[{"given":"Abhiraj","family":"Saxena","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA 19107,","place":["United States"]},{"name":"Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ 08901,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Yorker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA 19107,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A","family":"Zorko","sequence":"additional","affiliation":[{"name":"Department of Medicine, Masonic Cancer Center, University of Minnesota-Twin Cities , Minneapolis, MN 55455,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA 19104,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal A","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biren","family":"Saraiya","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ 08901,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Tester","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA 19107,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J","family":"Mille","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA 19107,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L","family":"Shaver","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA 19107,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-9772","authenticated-orcid":false,"given":"Nikita","family":"Nikita","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA 19107,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-7737","authenticated-orcid":false,"given":"Grace L","family":"Lu-Yao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA 19107,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Kevin","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA 19107,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-2317","authenticated-orcid":false,"given":"Kevin K","family":"Zarrabi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA 19107,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"2026060408370511200_oyag172-B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026060408370511200_oyag172-B2","doi-asserted-by":"publisher","first-page":"13097","DOI":"10.3390\/ijms222313097","article-title":"A review of prostate organogenesis and a role for iPSC-derived prostate organoids to study prostate development and disease","volume":"22","author":"Buskin","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026060408370511200_oyag172-B3","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study","volume":"4","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026060408370511200_oyag172-B4","doi-asserted-by":"publisher","first-page":"e222246","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026060408370511200_oyag172-B5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","article-title":"Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States","volume":"4","author":"Kelly","year":"2018","journal-title":"Eur Urol Focus"},{"key":"2026060408370511200_oyag172-B6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/21681805.2022.2070275","article-title":"Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists","volume":"56","author":"Bonde","year":"2022","journal-title":"Scand J Urol"},{"key":"2026060408370511200_oyag172-B7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/biomedicines9091247","article-title":"Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Henriquez","year":"2021","journal-title":"Biomedicines"},{"key":"2026060408370511200_oyag172-B8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2016.06.011","article-title":"Predictors of time to metastasis in castration-resistant prostate cancer","volume":"96","author":"Moreira","year":"2016","journal-title":"Urology"},{"key":"2026060408370511200_oyag172-B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026060408370511200_oyag172-B10","doi-asserted-by":"publisher","first-page":"S957","DOI":"10.1016\/j.annonc.2023.09.2721","article-title":"1771MO pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): randomized double-blind phase III KEYNOTE-641 study","volume":"34","author":"Graff","year":"2023","journal-title":"Ann Oncol"},{"key":"2026060408370511200_oyag172-B11","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO-24-01283","article-title":"Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic Castration-Resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial","volume":"43","author":"Petrylak","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026060408370511200_oyag172-B12","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.7150\/thno.73152","article-title":"Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","volume":"12","author":"Ma","year":"2022","journal-title":"Theranostics"},{"key":"2026060408370511200_oyag172-B13","doi-asserted-by":"publisher","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"2026060408370511200_oyag172-B14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J Hematol Oncol"},{"key":"2026060408370511200_oyag172-B15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw7888","article-title":"A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies","volume":"12","author":"Skokos","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026060408370511200_oyag172-B16","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: Current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"2026060408370511200_oyag172-B17","doi-asserted-by":"publisher","first-page":"17562872231182219","DOI":"10.1177\/17562872231182219","article-title":"Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Ther Adv Urol"},{"key":"2026060408370511200_oyag172-B18","doi-asserted-by":"publisher","first-page":"2356820","DOI":"10.1080\/15384047.2024.2356820","article-title":"T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer","volume":"25","author":"Palecki","year":"2024","journal-title":"Cancer Biol Ther"},{"key":"2026060408370511200_oyag172-B19","author":"Junghans"},{"key":"2026060408370511200_oyag172-B20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE((R)) immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"2026060408370511200_oyag172-B21","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1200\/JCO.2021.39.15_suppl.5013","article-title":"Results of an ongoing phase 1\/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"39","author":"Bono","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026060408370511200_oyag172-B22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1200\/JCO.2022.40.6_suppl.094","article-title":"Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC","volume":"40","author":"McKean","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026060408370511200_oyag172-B23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1200\/JCO.2022.40.6_suppl.098","article-title":"Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Slovin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026060408370511200_oyag172-B24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"2026060408370511200_oyag172-B25","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae313","article-title":"A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer","volume":"30","author":"Calvo","year":"2025","journal-title":"Oncologist"},{"key":"2026060408370511200_oyag172-B26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"2026060408370511200_oyag172-B27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/JCO.2023.41.6_suppl.153","article-title":"Early dose escalation of LAVA-1207, a novel bispecific gamma-Delta T-cell engager (gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Mehra","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"2026060408370511200_oyag172-B28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1158\/1078-0432.CCR-22-1601","article-title":"Phase II trial of pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer","volume":"29","author":"Vaishampayan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026060408370511200_oyag172-B29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 x CD3 XmAb 2\u2009+\u20091 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"key":"2026060408370511200_oyag172-B30","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026060408370511200_oyag172-B31","doi-asserted-by":"publisher","first-page":"e14587","DOI":"10.1200\/JCO.2024.42.16_suppl.e14587","article-title":"Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Falchook","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"2026060408370511200_oyag172-B32","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1200\/JCO.2024.42.16_suppl.2536","article-title":"Updated results on the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancer","volume":"42","author":"Heitmann","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"2026060408370511200_oyag172-B33","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"key":"2026060408370511200_oyag172-B34","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a first-in-class, bispecific T-Cell engager targeting human kallikrein 2, in metastatic Castration-Resistant prostate cancer: a phase I study","volume":"43","author":"Stein","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026060408370511200_oyag172-B35","doi-asserted-by":"publisher","first-page":"CT064","DOI":"10.1158\/1538-7445.Am2025-ct064","article-title":"Abstract CT064: updated safety and efficacy results from a phase 1\/2 study of nezastomig, a first-in-class co-stimulatory PSMA\u00d7CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"85","author":"Siddiqui","year":"2025","journal-title":"Cancer Res"},{"key":"2026060408370511200_oyag172-B36","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026060408370511200_oyag172-B37","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","article-title":"Promises and challenges of adoptive T-cell therapies for solid tumours","volume":"124","author":"Morotti","year":"2021","journal-title":"Br J Cancer"},{"key":"2026060408370511200_oyag172-B38","doi-asserted-by":"publisher","first-page":"TPS5118","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5118","article-title":"Trial in progress (XALute): phase 3 study of xaluritamig vs investigator\u2019s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Kelly","year":"2025","journal-title":"Journal of Clinical Oncology"},{"key":"2026060408370511200_oyag172-B39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1358\/dot.2022.58.6.3378055","article-title":"Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma","volume":"58","author":"Deshpande","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"2026060408370511200_oyag172-B40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2022","journal-title":"Future Oncol"},{"key":"2026060408370511200_oyag172-B41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2026060408370511200_oyag172-B42","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2026060408370511200_oyag172-B43","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and malignant human tissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J Surg"},{"key":"2026060408370511200_oyag172-B44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003766","article-title":"JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy","volume":"10","author":"Leclercq","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag172\/68208065\/oyag172.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag172\/68208065\/oyag172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag172\/68208065\/oyag172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:37:13Z","timestamp":1780576633000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag172\/8666983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag172","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,2]]},"article-number":"oyag172"}}